Antiplatelet therapy in early management of non-ST-segment elevation acute coronary syndrome: The 2002 and 2007 guidelines from North America and Europe

Journal of Cardiovascular Pharmacology

Volumn 51, Issue 5, 2008, Pages 425-433

  Thomas, Deepak ^a   Giugliano, Robert P ^b,c  

^a Department of Nuclear Cardiology ^*  (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c TIMI Study Office   (United States)

Author keywords

Glycoprotein IIb IIIa inhibitors; Guidelines; Myocardial infarction; Non ST elevation acute coronary syndrome; Percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROTON PUMP INHIBITOR; ROFECOXIB; TICLOPIDINE; TIROFIBAN; WARFARIN; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY STENT; DRUG COATING; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG PROTEIN BINDING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPEPSIA; EUROPE; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE PERSONNEL; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; LOADING DRUG DOSE; LOW DRUG DOSE; MAINTENANCE THERAPY; MEDICAL SOCIETY; MONOTHERAPY; NAUSEA; NEUTROPENIA; NORTH AMERICA; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RECURRENT DISEASE; REVIEW; ST SEGMENT ELEVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREATMENT INDICATION; UNSTABLE ANGINA PECTORIS; COMPARATIVE STUDY; DRUG ANTAGONISM;

ACUTE CORONARY SYNDROME; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; EUROPE; HUMANS; NORTH AMERICA; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PRACTICE GUIDELINES AS TOPIC; TICLOPIDINE;

EID: 55949090397     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31816a35a2     Document Type: Review

References (45)

1. Anderson JF, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction). J Am Coll Cardiol. 2007;50:e1-157.
2. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J. 2007;28:1598-1660.
3. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2002;40:1366-1374.
4. Bertrand ME, Simoons ML, Fox KA, et al. For the Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2002; 23:1809-1840.
5. Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995;310:827-830.
6. Hsu J, Pack Q, Feldstein DA. Clinical use of evidence-based medicine-clinical questions. Is low-dose aspirin a better choice in patients with coronary artery disease and bleeding risks? WMJ. 2007; 106:7-8.
7. Serebruany VL, Steinhubl SR. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol. 2005;95:1218-1222.
8. Colwell JA. Aspirin for the primary prevention of cardiovascular events. Drugs Today (Barc). 2006;42:467-479.
9. Laine L. Review article: gastrointestinal bleeding with low-dose aspirin - what's the risk? Aliment Pharmacol Ther. 2006;24:897-908.
10. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
11. Love BB, Biller J, Gent M. Adverse haematological effects of ticlopidine. Prevention, recognition and management. Drug Saf. 1998;19:89-98.
12. Creager MA. Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events. Vasc Med. 1998;3:257-260.
13. Bhatt DL, Fox KA, Hacke W, et al. For the CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706-1717.
14. Gerschutz GP, Bhatt DL. The CURE trial: using clopidogrel in acute coronary syndromes without ST-segment elevation. Cleve Clin J Med. 2002;69:377-382.
15. Yusuf S, Zhao F, Mehta SR, et al. For the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
16. Smith SM, Judge HM, Peters G, et al. Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy. Platelets. 2006;17:250-258.
17. McCabe DJ, Harrison P, Mackie IJ, et al. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. Platelets. 2005; 16:269-280.
18. Pettersen AA, Seljeflot I, Abdelnoor M, et al. Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. Scand Cardiovasc J. 2004;38:353-356.
19. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809-1817.
20. van Hecken A, Depré M, Wynants K, et al. Effect of clopidogrel on naproxen-induced gastrointestinal blood loss in healthy volunteers. Drug Metabol Drug Interact. 1998;14:193-205.
21. Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006; 113:2906-2913.
22. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet. 1999; 353:227-231.
23. Coller BS. Monitoring platelet GP IIb/IIIa [corrected] antagonist therapy. Circulation. 1997;96:3828-3832.
24. Montalescot G, Sideris G, Meuleman C, et al. For the ALBION Trial Investigators. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol. 2006;48:931-938.
25. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA. 2000;284:835-842.
26. Fox KA, Dabbous OH, Goldberg RJ, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ 2006;333:1091.
27. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002;359:189-198.
28. Cannon CP, Weintraub WS, Demopoulos LA, et al. For the TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy)-Thrombolysis in Myocardial Infarction 18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;34: 1879-1887.
29. Nguyen MC, Lim YL, Walton A, et al. For the GRACE Investigators. Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent? Eur Heart J. 2007;28:1717-1722.
30. Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347:969-974.
31. Stenestrand U, Lindbäck J, Wallentin L. RIKS-HIA Registry. Anti-coagulation therapy in atrial fibrillation in combination with acute myocardial infarction influences long-term outcome: a prospective cohort study from the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA). Circulation. 2005; 112: 3225-3231.
32. Eriksson P. Long-term clopidogrel therapy after percutaneous coronary intervention in PCI-CURE and CREDO: the "Emperor's New Clothes" revisited. Eur Heart J. 2004;25:720-722.
33. Fox KA, Mehta SR, Peters R, et al. Clopidogrel in unstable angina to prevent recurrent ischemic events trial. benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation. 2004;110:1202-1208.
34. Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading dose of clopidogrel for reduction of peri-procedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty) study. Circulation. 2005;111:2099-2106.
35. Mehta SR. Clopidogrel in non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2006; 8(Suppl G):G25-G30.
36. PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study investigators. N Engl J Med. 1998;338:1488-1497.
37. Gurbel PA, Bliden KP, Zaman KA, et al. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation. 2005;111:1153-1159.
38. Kastrati A, Mehilli J, Neumann FJ, et al. For the ISAR-REACT 2 Trial Investigators. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pre-treatment: the ISAR-REACT 2 randomized trial. JAMA. 2006;295:1531-1538.
39. Ndrepepa G, Kastrati A, Mehilli J, et al. One-year clinical outcomes with abciximab vs placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT-2 randomized trial. Eur Heart J. 2008;29:455-461.
40. Giugliano RP, Braunwald E. The year in non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2006;48:386-95.
41. Giugliano RP, Newby LK, Harrington RA, et al, For the EARLY ACS Steering Committee. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome - study design and rationale. Am Heart J. 2005;149:994-1002.
42. Stone GW, McLaurin BT, Cox DA, et al. For the ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355:2203-2216.
43. Stone GW, Ware JH, Betrand ME, et al for the ACUITY Investigators. Anthithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. JAMA. 2007;298:2497-2506.
44. Alexander KP, Chen AY, Roe MT, et al. For the CRUSADE Investigators. Excess dosing of antiplatelet and antithrombin agents in the treatment of non - ST-segment elevation acute coronary syndromes. JAMA. 2005;294: 3108-3116.
45. Kirtane AJ, Piazza G, Murphy SA, et al. For the TIMI Study Group. Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial. J Am Coll Cardiol. 2006;47:2374-2379.